Muscle Wasting Disorders - Pipeline Review, Q3 2011

Date: July 1, 2011
Pages: 112
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M585C588ABDEN
Leaflet:

Download PDF Leaflet

Muscle Wasting Disorders - Pipeline Review, Q3 2011
Muscle Wasting Disorders - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Muscle Wasting Disorders - Pipeline Review, Q3 2011', provides an overview of the Muscle Wasting Disorders therapeutic pipeline. This report provides information on the therapeutic development for Muscle Wasting Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Muscle Wasting Disorders. 'Muscle Wasting Disorders - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Muscle Wasting Disorders.
  • A review of the Muscle Wasting Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Muscle Wasting Disorders pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Muscle Wasting Disorders.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Muscle Wasting Disorders pipeline depth and focus of Muscle Wasting Disorders therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Muscle Wasting Disorders Overview
Therapeutics Development
An Overview of Pipeline Products for Muscle Wasting Disorders
Muscle Wasting Disorders Therapeutics under Development by Companies
Muscle Wasting Disorders Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Muscle Wasting Disorders Therapeutics - Products under Development by Companies
Muscle Wasting Disorders Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Muscle Wasting Disorders Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
QLT Inc.
Inovio Biomedical Corporation
Daiichi Sankyo Company, Ltd
BioLineRx, Ltd.
GTx, Inc.
Pfizer Inc.
Rigel Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
Insmed Incorporated
Ligand Pharmaceuticals Incorporated
Repligen Corporation
Theratechnologies Inc.
Galapagos NV
Santhera Pharmaceuticals Holding AG
The Avicena Group, Inc.
Helsinn Healthcare S.A.
Quigley Pharma, Inc.
NovImmune SA
Vicus Therapeutics, LLC
OHR Pharmaceutical Inc.
Acacia Pharma Ltd.
Rhythm Pharmaceuticals
Muscle Wasting Disorders - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
SUN11031 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Ostarine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Iplex - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
RM-131 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
BL-5040 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
NI-1201 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Tesamorelin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
BMS-945429 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
DMD-02 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
LGD-4033 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
LGD-4033 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
RG3039 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
VGX-3200 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Kanglaite - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Remicade - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Omigapil - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
G100192 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Drug for Myotonic Dystrophy Type 1 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
QR-443 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Tetracyclines for SMA - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
GLPG0492 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Atrigel-GHRP-1 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Ghrelin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Enbrel - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
N-Acetylcysteine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Anamorelin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
APD209 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
BL-6020 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Testosterone - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Testosterone + Finasteride - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Finasteride - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Testosterone + Recombinant Human Growth Hormone - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Dronabinol + Megestrol - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Testosterone - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
VT-122 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
ACVR 2Beta - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Eicosapentaenoic Acid - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
OHR/AVR118 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
VT-122 + Nexavar - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
MT-102 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Revlimid - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
PF-05230901 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Remicade + Gemcitabine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Muscle Wasting Disorders Therapeutics – Drug Profile Updates
Muscle Wasting Disorders Therapeutics - Discontinued Products
Muscle Wasting Disorders - Featured News
Jul 20, 2011: Galapagos Initiates Proof-of-Mechanism Clinical Study Of Candidate Cachexia Drug GLPG0492
Jun 06, 2011: Ligand Presents Multi-Dose Phase I Data On Lead SARM Molecule LGD-4033 At Endocrine Society Annual Meeting
Jun 06, 2011: GTx Announces Agreement With FDA On Phase III Clinical Development Plan Of Ostarine For Treatment Of Muscle Wasting In Patients With NSCLC
May 18, 2011: GTx Announces ASCO Presentations Highlighting Effects Of Ostarine On Physical Function And Survival In Patients With Non-Small Cell Lung Cancer
May 17, 2011: Ohr Pharmaceutical Receives Canadian Composition-of-Matter Patent For OHR/AVR118
Mar 17, 2011: PsiOxus Therapeutics Initiates Phase II Clinical Study Of Wasting Disease Therapeutic MT-102
Dec 27, 2010: Vicus Initiates Phase II Trial To Evaluate VT-122 In Patients With Liver Cancer Receiving Nexavar
Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics
Dec 14, 2010: Ohr Enrolls First Three Patients In Phase IIb Cachexia Trial
Dec 02, 2010: Galapagos Successfully Completes First-In-Human Trial Of GLPG0492 In Cachexia Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 112

LIST OF TABLES

Number of Products Under Development for Muscle Wasting Disorders, Q3 2011
Products under Development for Muscle Wasting Disorders – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Bristol-Myers Squibb Company, 2011
Johnson & Johnson, 2011
QLT Inc., 2011
Inovio Biomedical Corporation, 2011
Daiichi Sankyo Company, Ltd, 2011
BioLineRx, Ltd., 2011
GTx, Inc., 2011
Pfizer Inc., 2011
Rigel Pharmaceuticals, Inc., 2011
Paratek Pharmaceuticals, Inc., 2011
Insmed Incorporated, 2011
Ligand Pharmaceuticals Incorporated, 2011
Repligen Corporation, 2011
Theratechnologies Inc., 2011
Galapagos NV, 2011
Santhera Pharmaceuticals Holding AG, 2011
The Avicena Group, Inc., 2011
Helsinn Healthcare S.A., 2011
Quigley Pharma, Inc., 2011
NovImmune SA, 2011
Vicus Therapeutics, LLC, 2011
OHR Pharmaceutical Inc., 2011
Acacia Pharma Ltd., 2011
Rhythm Pharmaceuticals, 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Muscle Wasting Disorders Therapeutics – Drug Profile Updates
Discontinued Products 102

LIST OF FIGURES

Number of Products under Development for Muscle Wasting Disorders, Q3 2011
Products under Development for Muscle Wasting Disorders – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Discovery and Pre-Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011 42
Muscle Wasting Disorders - Pipeline Review, Q1 2011 US$ 500.00 Jan, 2011 · 42 pages
Growth Disorders - Pipeline Review, H2 2013 US$ 2,000.00 Aug, 2013 · 67 pages
Menopausal Disorders - Pipeline Review, Q4 2010 US$ 500.00 Dec, 2010 · 40 pages
Sleep Disorders - Pipeline Review, Q1 2011 US$ 500.00 Jan, 2011 · 72 pages

Ask Your Question

Muscle Wasting Disorders - Pipeline Review, Q3 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: